HC Wainwright Has Bullish Forecast for VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at HC Wainwright increased their FY2024 EPS estimates for Voyager Therapeutics in a research note issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.82) per share for the year, up from their previous forecast of ($0.97). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($1.69) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter last year, the business posted ($0.59) EPS.

A number of other equities research analysts have also recently commented on VYGR. Leerink Partners began coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. Wedbush dropped their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Trading Down 2.1 %

Shares of Voyager Therapeutics stock opened at $5.27 on Monday. The business’s fifty day simple moving average is $6.59 and its 200 day simple moving average is $7.45. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $11.72. The firm has a market capitalization of $287.90 million, a P/E ratio of 7.42 and a beta of 0.89.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of VYGR. Barclays PLC lifted its stake in Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after buying an additional 6,740 shares in the last quarter. Erste Asset Management GmbH bought a new stake in Voyager Therapeutics during the third quarter valued at $6,192,000. Verition Fund Management LLC purchased a new position in Voyager Therapeutics during the third quarter worth about $216,000. Finally, BNP Paribas Financial Markets increased its stake in Voyager Therapeutics by 30.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock worth $288,000 after acquiring an additional 11,516 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. The trade was a 6.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.